Table 3.
Mouse models with implications in endometriosis and endometriosis-associated ovarian cancers.
| Genotype | Phenotype | Penetrance | Details | Ref. |
|---|---|---|---|---|
| Arid1af/f;AdCre (Ovarian bursa) | No cancer | 0/29 with adnexal masses 0/42 with adnexal masses |
No endometriosis | [157,158] |
| Arid1af/f;Amhr2Cre | No cancer | 0/20 with adnexal masses | No endometriosis | [159] |
| Arid1af/f;PgrCre | No cancer | 0/20 with adnexal masses | No endometriosis | [160] |
| Ptenf/f;AdCre (Ovarian bursa) | No cancer | 0/5 with adnexal masses 0/63 with adnexal masses |
No endometriosis | [158,161] |
| Ptenf/f;AdCre (Infundibulum to ovarian bursa) | Low penetrance endometrioid ovarian cancer at 26 weeks | 8/13 with ovarian endometriosis like lesions 1/13 with ovarian cancer by 26 weeks |
Endometriosis-like lesions of ovary (lacked stromal component) | [162] |
| Ptenf/f;Cyp19Cre | No cancer | 0/4 with adnexal masses | No endometriosis | [163] |
| Ptenf/f;Amhr2Cre | Granulosa cell tumor | 5/70 with ovarian cancers by 7 months | No endometriosis | [164] |
| Ptenf/f;Apcf/f;Ovgp1Cre | Endometrioid ovarian carcinoma | 10/15 with ovarian cancers | Metastatic lesions | [146] |
| Ptenf/f; Pax8Cre | Endometrioid oviductal adenocarcinoma | 3/4 with oviductal cancers by 7 months | Oviductal tumors metastasized to ovary | [147] |
| Pik3caH1047R;AdCre (Ovarian bursa) | No cancer | 0/6 with adnexal masses | 4/5 ovarian surface epithelium hyperplasia (microscopic) | [157] |
| KrasG12D;AdCre (Infundibulum to ovarian bursa) | 15/15 endometriosis-like lesions of ovary | 15/15 with endometriosis-like lesions of ovary | Endometriosis-like lesions of ovary (lacked stromal component) | [162] |
| KrasG12D;AdCre (Uterotubal injection to ovarian bursa) | 7/15 with peritoneal endometriosis | 7/15 with peritoneal endometriosis | Peritoneal endometriosis | [162] |
| KrasG12D;AdCre (IP injection) | No cancer | 0/13 with adnexal masses | No endometriosis | [162] |
| KrasG12D; Amhr2Cre | No cancer | 0/4 with adnexal masses | No endometriosis Abnormal follicles |
[145,163] |
| KrasG12D; Cyp19Cre | No cancer | 0/4 with adnexal masses | No endometriosis Abnormal follicles |
[145,163] |
| KrasG12D; PgrCre | No cancer | 0/3 with adnexal masses | No endometriosis | [163] |
| Ctnnb1f/+;Amhr2Cre | Endometrioid ovarian carcinoma | 5/6 with ovarian cancer by 6 months | No endometriosis | [165] |
| Arid1af/f;Pik3caH1047R;AdCre (Ovarian bursa) | Poorly differentiated clear-cell ovarian carcinoma | 23/30 with ovarian cancer by 7 weeks | 77% penetrance No endometriosis Aggressive metastatic tumors |
[157] |
| Arid1af/f;Ptenf/f;AdCre (Ovarian bursa) | 5/13 endometrioid ovarian carcinoma 8/13 undifferentiated adenocarcinoma |
13/22 with ovarian cancer by 9 months | 59% penetrance No endometriosis Aggressive undifferentiated tumors |
[158] |
| Apcf/f;PgrCre | Endometrioid ovarian carcinoma | 12/43 with ovarian cancer | No endometriosis 16% endometrioid ovarian cysts |
[166] |
| Ptenf/f;Apcf/f;AdCre (Ovarian bursa) | Endometrioid ovarian carcinoma | 29/29 with ovarian cancer | 100% penetrance No endometriosis Aggressive metastatic tumors |
[161] |
| Ptenf/f;Apcf/f;Pik3caH1047R;AdCre (Ovarian bursa) | Endometrioid ovarian carcinoma | 11/11 with ovarian cancer | No endometriosis Aggressive metastatic tumors |
[167] |
| KrasG12D;Ptenf/f;AdCre (Infundibulum to ovarian bursa) | Endometrioid ovarian carcinoma | 9/9 with ovarian cancer by 12 weeks | 100% penetrance Aggressive metastatic disease No endometriosis |
[162] |
| MUC1+/-;KrasG12D;AdCre (Ovarian bursa) | Endometriosis-like lesions of ovary | No ovarian cancer | endometriosis-like lesions of ovary | [168] |
| Ctnnb1f/+;Ptenf/f;Amhr2Cre | Endometrioid ovarian carcinoma | 5/5 with ovarian cancer by 6 weeks | No endometriosis | [165] |
| KrasG12D; Ptenf/f; Amhr2Cre | Low grade ovarian serous papillary adenocarcinomas | 100% with ovarian tumors by 10 weeks | No endometriosis | [143,163] |
| KrasG12D; Ptenf/f; PgrCre | No cancer | 0/3 with adnexal masses | No endometriosis | [163] |
| KrasG12D; Ptenf/f; Cyp19Cre | No cancer | 0/3 with adnexal masses | No endometriosis | [163] |